medigraphic.com
Instituto Nacional de Salud Pública

2019, Number 2

<< Back

salud publica mex 2019; 61 (2)

Coalición para el estudio de la hepatitis C en México. Priority actions towards a national program for detection, treatment, and monitoring of patients with hepatitis C

Wolpert-Barraza E, Muñoz-Hernández O, Kershenobich-Stalnikowitz D

Language: Spanish
References: 16
Page: 212-216
PDF size: 361.49 Kb.


ABSTRACT

In the Mexican health scenario, the hepatitis C virus epidemic is present, along with its comorbidities and premature mortality. Acting immediately will allow its containment in short term with the proper implementation of the current available tools for prevention, diagnosis and highly effective pharmacological therapies. The Coalition for the study of hepatitis C in Mexico has developed a position paper that takes advantage of these containment measures and presents the development of a National program for the detection, timely treatment and follow-up of patients with hepatitis C.


REFERENCES

  1. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081-8. https://doi.org/10.1016/S0140-6736(16)30579-7

  2. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-76. https://doi.org/10.1016/ S2468-1253(16)30181-9

  3. World Health Organization. Global Hepatitis Report 2017. Geneva: WHO, 2017. Disponible en: http://www.who.int/hepatitis/publications/ global-hepatitis-report2017/en/

  4. Kershenobich D, Razavi HA, Sánchez-Ávila JF, Bessone F, Coelho HS, Dagher L, et al. Trends and projections on hepatitis C virus epidemiology in Latin America. Liver Int. 2011;31(suppl 2):18-29. https://doi.org/10.1111/ j.1478-3231.2011.02538.x

  5. Szabo SM, Bibby M, Yuan Y, Donato BM, Jiménez-Méndez R, Castañeda- Hernández G, et al. The epidemiologic burden of hepatitis C virus infection in Latin America Ann Hepatol 2012;11(5):623-35.

  6. Corona-Lau C, Muñoz L, Wolpert E, Aguilar LM, Dehesa M, Gutiérrez C, et al. Hepatitis C screening in the general population. Rev Invest Clin. 2015;67:104-8.

  7. Kershenobich D, Aguilar-Valenzuela LM, Muñoz L. Vicisitudes de la hepatitis C en México. Rev Invest Clin. 2014;66(4):299-302.

  8. Gutiérrez JP, Sucilla-Pérez H, Conde-González CJ, Izazola JA, Romero- Martínez M, Hernández-Ávila M. Disminución de la seroprevalencia de hepatitis C en México: resultados de la Ensanut 2012. Salud Publica Mex. 2016;58(1):25-32. https://doi.org/10.21149/spm.v58i1.7664

  9. GBD Compare [internet]. Seattle, WA: Institute for Health Metrics and Evaluation. c2015- [cited 2015 October 13]. Available from http://vizhub. healthdata.org/gbd-compare

  10. Westbrook RH, Dusheiko G. Natural History of hepatitis C. J Hepatol. 2014;61:S58-68. https://doi.org/10.1016/j.jhep.2014.07.012

  11. Wolpert E, Kershenobich D, Dehesa M, Hernández-Ávila M, Alpuche- Aranda CM, López-Gatell RH, et al. Documento Ejecutivo de apoyo a las autoridades de Salud para el desarrollo del Plan nacional de prevención y control de la hepatitis C en México. Ciudad de México: Coalición para el estudio de la hepatitis C en México, 2017.

  12. Chirino-Sprung RA, Dehesa M, Wolpert E, Corona-Lau C, García- Juárez I, Sánchez-Ávila JF, et al. Chronic hepatitis C treatment with directacting antiviral agents in a real-life setting. Rev Invest Clin. 2016;68:203-12.

  13. Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, et al. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex. 2018;83:275-324. https://doi.org/10.1016/j.rgmx.2017.11.001

  14. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511. https://doi.org/10.1016/j.jhep.2018.03.026

  15. Rojo-Medina J, Bello-López JM. National prevalence of hepatitis C and B viruses in Mexican blood donors, 2000-2012. Rev Med Hosp Gen Méx. 2017;80:37-44. https://doi.org/10.1016/j.hgmx.2016.07.002

  16. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin Liver Dis. 2000;20(1):17-36. https://doi.org/10.1055/s-2000-9505




2020     |     www.medigraphic.com